Effects of Sinus Rhythm Maintenance on Left Heart Function After Electrical Cardioversion of Atrial Fibrillation: Implications for Tachycardia-Induced Cardiomyopathy

2015 ◽  
Vol 31 (1) ◽  
pp. 36-43 ◽  
Author(s):  
Andreas J. Zimmermann ◽  
Matthias Bossard ◽  
Stefanie Aeschbacher ◽  
Tobias Schoen ◽  
Gian Voellmin ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Heart Function ◽  
Electrical Cardioversion ◽  
Left Heart ◽  
Left Heart Function ◽  
Tachycardia Induced Cardiomyopathy ◽  
Sinus Rhythm Maintenance

The Predictive Value of Transthoracic Echocardiographic Variables for Sinus Rhythm Maintenance after Electrical Cardioversion of Atrial Fibrillation

Cardiology ◽  
2008 ◽  
Vol 111 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Irene Grundvold ◽  
Arnljot Tveit ◽  
Pål Smith ◽  
Ingebjørg Seljeflot ◽  
Michael Abdelnoor ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Predictive Value ◽  
Electrical Cardioversion ◽  
Sinus Rhythm Maintenance

Systematic analysis of ECG predictors of sinus rhythm maintenance after electrical cardioversion for persistent atrial fibrillation

Heart Rhythm ◽  
2016 ◽  
Vol 13 (5) ◽  
pp. 1020-1027 ◽  
Author(s):  
Theo Lankveld ◽  
Cees B. de Vos ◽  
Ione Limantoro ◽  
Stef Zeemering ◽  
Elton Dudink ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Rhythm ◽  
Persistent Atrial Fibrillation ◽  
Electrical Cardioversion ◽  
Systematic Analysis ◽  
Sinus Rhythm Maintenance

scholarly journals Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias

2021 ◽  
Vol 10 (7) ◽  
pp. 1456
Author(s):  
Carlo Lavalle ◽  
Michele Magnocavallo ◽  
Martina Straito ◽  
Luca Santini ◽  
Giovanni Battista Forleo ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ventricular Tachycardia ◽  
Drug Treatment ◽  
Sinus Rhythm ◽  
Antiarrhythmic Drug ◽  
Safety Profile ◽  
Patient Management ◽  
Clinical Use ◽  
Supraventricular Arrhythmias ◽  
Sinus Rhythm Maintenance

Transcatheter ablation was increasingly and successfully used to treat symptomatic drug refractory patients affected by supraventricular arrhythmias. Antiarrhythmic drug treatment still plays a major role in patient management, alone or combined with non-pharmacological therapies. Flecainide is an IC antiarrhythmic drug approved in 1984 from the Food and Drug Administration for the suppression of sustained ventricular tachycardia and later for acute cardioversion of atrial fibrillation and for sinus rhythm maintenance. Currently, flecainide is mostly used for sinus rhythm maintenance in atrial fibrillation (AF) patients without structural cardiomyopathy although recent studies enrolling different patient populations have demonstrated a good effectiveness and safety profile. How should we interpret the results of the CAST after the latest evidence? Is it possible to expand the indications of flecainide, and therefore, its use? This review aims to highlight the main characteristics of flecainide, as well as its optimal clinical use, delineating drug indications and contraindications and appropriate monitoring, based on the most recent evidence.

Sign in / Sign up

Export Citation Format

Share Document